TimesSquare Capital Management
TARS icon

TimesSquare Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

TimesSquare Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25.5M Sell
324,765
-44,612
-12% -$3.1M 0.42% 83
2026
Q2 		$23.2M Sell
369,377
-19,213
-5% -$1.23M 0.34% 97
2026
Q1 		$27.3M Buy
388,590
+56,144
+17% +$3.92M 0.46% 82
2025
Q4 		$27.2M Buy
332,446
+64,941
+24% +$4.85M 0.41% 96
2025
Q3 		$15.9M Buy
+267,505
New +$13.2M 0.23% 132
2023
Q2 		– Sell
-1,192,660
Closed -$15M – 187
2023
Q1 		$15M Sell
1,192,660
-236,650
-17% -$3.46M 0.22% 143
2022
Q4 		$21M Sell
1,429,310
-90,600
-6% -$1.5M 0.3% 129
2022
Q3 		$26M Buy
1,519,910
+38,200
+3% +$607K 0.36% 125
2022
Q2 		$21.6M Buy
1,481,710
+822,110
+125% +$12.3M 0.3% 131
2022
Q1 		$11.1M Sell
659,600
-1,200
-0.2% -$22.3K 0.12% 167
2021
Q4 		$14.9M Buy
660,800
+10,020
+2% +$261K 0.13% 175
2021
Q3 		$14M Sell
650,780
-35,925
-5% -$889K 0.12% 192
2021
Q2 		$19.9M Buy
686,705
+234,805
+52% +$7.33M 0.16% 180
2021
Q1 		$14.6M Sell
451,900
-12,700
-3% -$470K 0.12% 186
2020
Q4 		$19.2M Buy
+464,600
New +$13.2M 0.16% 181

Other funds holding TARS

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

TimesSquare Capital Management's TARS Position: Q3 2026 in Review

TimesSquare Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 12% in Q3 2026, selling an estimated $3.1M and leaving 324,765 shares worth $25.5M. The position accounts for 0.42% of the portfolio, ranked #83.

TimesSquare Capital Management first reported a position in TARS in Q4 2020 and has held it in 15 quarters since. The position peaked at $27.3M in Q1 2026. 176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • TimesSquare Capital Management held 324,765 shares of Tarsus Pharmaceuticals worth $25.5M as of Q3 2026.
  • TimesSquare Capital Management sold 44,612 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $3.1M.
  • Tarsus Pharmaceuticals made up 0.42% of TimesSquare Capital Management's portfolio in Q3 2026, its #83 holding.
  • TimesSquare Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
  • TimesSquare Capital Management's Tarsus Pharmaceuticals position peaked at $27.3M in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on TimesSquare Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.